Literature DB >> 27774124

Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds.

Jiradanai Sarasamkan1, Matthias Scheunemann2, Nattayaporn Apaijai3, Siripong Palee3, Warisara Parichatikanond4, Kuntarat Arunrungvichian5, Steffen Fischer2, Siriporn Chattipakorn3, Winnie Deuther-Conrad2, Gerrit Schüürmann6, Peter Brust2, Opa Vajragupta5.   

Abstract

The novel quinuclidine anti-1,2,3-triazole derivatives T1-T6 were designed based on the structure of QND8. The binding studies revealed that the stereochemistry at the C3 position of the quinuclidine scaffold plays an important role in the nAChR subtype selectivity. Whereas the (R)-enantiomers are selective to α7 over α4β2 (by factors of 44-225) and to a smaller degree over α3β4 (3-33), their (S)-counterparts prefer α3β4 over α4β2 (62-237) as well as over α7 (5-294). The (R)-derivatives were highly selective to α7 over α3β4 subtypes compared to (RS)- and (R)-QND8. The (S)-enantiomers are 5-10 times more selective to α4β2 than their (R) forms. The overall strongest affinity is observed for the (S)-enantiomer binding to α3β4 (Ki, 2.25-19.5 nM) followed by their (R)-counterpart binding to α7 (Ki, 22.5-117 nM), with a significantly weaker (S)-enantiomer binding to α4β2 (Ki, 414-1980 nM) still above the very weak respective (R)-analogue affinity (Ki, 5059-10436 nM).

Entities:  

Keywords:  Nicotinic acetylcholine receptor; click chemistry; positron emission tomography; quinuclidine anti-1,2,3-triazole

Year:  2016        PMID: 27774124      PMCID: PMC5066149          DOI: 10.1021/acsmedchemlett.6b00146

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  32 in total

Review 1.  Structural and functional diversity of native brain neuronal nicotinic receptors.

Authors:  Cecilia Gotti; Francesco Clementi; Alice Fornari; Annalisa Gaimarri; Stefania Guiducci; Irene Manfredi; Milena Moretti; Patrizia Pedrazzi; Luca Pucci; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

2.  Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.

Authors:  Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

3.  Rational design of triazololipopeptides analogs of kisspeptin inducing a long-lasting increase of gonadotropins.

Authors:  Massimiliano Beltramo; Vincent Robert; Mathieu Galibert; Jean-Baptiste Madinier; Philippe Marceau; Hugues Dardente; Caroline Decourt; Nicolas De Roux; Didier Lomet; Agnès F Delmas; Alain Caraty; Vincent Aucagne
Journal:  J Med Chem       Date:  2015-04-13       Impact factor: 7.446

4.  Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?

Authors:  Olga D Taraschenko; Vishal Panchal; Isabelle M Maisonneuve; Stanley D Glick
Journal:  Eur J Pharmacol       Date:  2005-04-14       Impact factor: 4.432

5.  Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors.

Authors:  C W Luetje; J Patrick
Journal:  J Neurosci       Date:  1991-03       Impact factor: 6.167

6.  Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the α3β4 nicotinic acetylcholine receptor subtype.

Authors:  Carlo Matera; Marta Quadri; Miriam Sciaccaluga; Diego Yuri Pomè; Francesca Fasoli; Marco De Amici; Sergio Fucile; Cecilia Gotti; Clelia Dallanoce; Giovanni Grazioso
Journal:  Eur J Med Chem       Date:  2015-12-05       Impact factor: 6.514

Review 7.  Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment.

Authors:  Vanessa Mucchietto; Arianna Crespi; Francesca Fasoli; Francesco Clementi; Cecilia Gotti
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 8.  Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.

Authors:  Simon N Haydar; John Dunlop
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

9.  Nicotinic receptors in neurodegeneration.

Authors:  Inmaculada Posadas; Beatriz López-Hernández; Valentín Ceña
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

10.  α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.

Authors:  Jun Toyohara; Kenji Hashimoto
Journal:  Open Med Chem J       Date:  2010-05-27
View more
  3 in total

1.  Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the α7 nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation.

Authors:  Marta Quadri; Almin Silnović; Carlo Matera; Nicole A Horenstein; Clare Stokes; Marco De Amici; Roger L Papke; Clelia Dallanoce
Journal:  Eur J Med Chem       Date:  2018-10-11       Impact factor: 6.514

2.  In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [125I]Iodo-ASEM and [18F]ASEM as Radiotracers of Homo- and Heteromeric α7 Nicotinic Acetylcholine Receptors.

Authors:  Cornelius K Donat; Henrik H Hansen; Hanne D Hansen; Ronnie C Mease; Andrew G Horti; Martin G Pomper; Elina T L'Estrade; Matthias M Herth; Dan Peters; Gitte M Knudsen; Jens D Mikkelsen
Journal:  Molecules       Date:  2020-03-20       Impact factor: 4.411

3.  In Silico Finding of Key Interaction Mediated α3β4 and α7 Nicotinic Acetylcholine Receptor Ligand Selectivity of Quinuclidine-Triazole Chemotype.

Authors:  Kuntarat Arunrungvichian; Sumet Chongruchiroj; Jiradanai Sarasamkan; Gerrit Schüürmann; Peter Brust; Opa Vajragupta
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.